Why Antibody–Drug Conjugates Are Appearing in So Many Cancer Headlines

What an ADC is, in NCI's words

New trial results and new approvals keep putting antibody-drug conjugates in the news. They are usually shortened to ADCs.

NCI defines one as a substance made up of a monoclonal antibody chemically linked to a drug. The antibody binds to specific proteins or receptors found on certain types of cells, including cancer cells. The linked drug then enters those cells.

NCI's fuller description of one ADC makes the design easy to picture. The antibody is the delivery driver. It seeks out a protein on the cell surface, latches on, and the whole package is pulled inside. There the cargo drug is released.

This page explains federal sources. It is not medical advice and does not suggest a test or treatment.

Why "smart bomb" oversells it

The phrase gets used a lot. It hides three things that matter.

First, the target protein often appears on healthy cells too, just in smaller amounts. Second, the drug can come off its carrier before it arrives. Third, each product carries its own pattern of side effects, and some of them are serious.

Those are not hypothetical. They show up in the approval documents.

One real example, with its warning label

In August 2024, FDA granted accelerated approval to the ADC trastuzumab deruxtecan, often written as T-DXd, for people with any advanced solid cancer producing high levels of the HER2 protein, who had already had at least one previous treatment. NCI notes this made it the first ADC used in a tumor-agnostic way, meaning the biomarker mattered more than where the cancer started.

The approval rested on three midsized trials in which tumors shrank in many people, sometimes for months or years.

In the same approval, FDA highlighted that the drug can cause serious side effects, including a dangerous lung inflammation called interstitial lung disease. NCI reports that some patients in those trials died from it.

That is what a complete ADC story looks like. Benefit and harm reported together, in the same paragraph.

Same target does not mean same drug

Two ADCs can aim at the same protein and still behave nothing alike. The linked drug may differ. The chemical linker may differ. The dose, the schedule, and the side effects may all differ.

So results for one conjugate do not carry over to another, even when both are described as targeting the same marker. Our overview of targeted therapy explains the broader category, and what antibody-drug conjugate means unpacks the term itself.

Reading an ADC trial or approval

• What exact cancer, and what target?
• What was the comparison treatment?
• What was the main endpoint, and how long did benefit last?
• How many people reduced their dose or stopped treatment because of side effects?
• What did the biomarker rule require? A protein name alone does not say who was eligible.

That last point connects to tumor testing. NCI explains that some treatments only work for people whose cancers carry particular biomarkers, and biomarker testing is how that is established.

What an approval does not mean for you

• The word targeted describes how a drug is delivered, not a guarantee that only cancer cells are affected.
• Success in one cancer does not establish benefit in every cancer that carries the same target.
• Accelerated approval means the evidence was promising enough to allow use while more is gathered. It is not a final verdict.
• Eligibility depends on tumor testing, prior treatment, stage, and the exact wording of the label or trial criteria.

Serious side effects are part of the picture with any of these drugs. Our guide to side effects of cancer treatment covers what monitoring usually involves.

Questions about an ADC headline

• What target does this ADC use, and was my tumor tested for it?
• What treatment was it compared against?
• Which serious side effects need watching, and how are they caught early?
• Is this a full approval or an accelerated one?

How this article was prepared

An AI-assisted editorial system helped prepare this page. No named medical reviewer has reviewed it unless one is listed.

The National Cancer Information Foundation publishes Cancer Explained. This page is for learning. It is not medical advice and does not suggest a test or treatment.

See an error, old source, or unclear wording? Tell us.